5Anderson FA Jr, Wheeler HB, Goldberg RJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.Arch Intern Med,1991,151:933-938.
7Urokinase Pulmonary embolism trial: a national cooperative study. Circulation ,1973, 47:1-108.
8Goldhaber SZ, Kessler CM, Heit J, et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.Lancet,1988,2:293-298.
9Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism.Chest,1992,101(4 Suppl):183S-185S.
10Daniels LB, Parker JA, Patel SR, et al.Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.Am J Cardiol, 1997,80:184-188.
2Morrell NW,Adnot S,Archer SL, et al. Cellular and molecular ba- sis of pulmonary arterial hypertension [ J]. Am Coll Cardiol,2009, 54(1 Suppl) :S20 -31.
3Gross PL,Weitz JI. New anticoagulants for treatment of venous t- hromboembolism [ J ]. Arterioscler Thromb Vasc Biol,2008,28 ( 3 ) : 380 - 386.
4柳志红.肺动脉栓塞[M]北京:北京科学技术出版社,2004167-168.
5Morrell NW,Adnot S,Archer SL. Cellular and molecular basis of pulmonary arterial hypertension[J].Journal of the American College of Cardiology,2009,(1 Suppl):S20-S31.
6Gross P L,Weitz J I. New anticoagulants for treatment of venous thromboembolism[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2008,(03):380-386.doi:10.1161/ATVBAHA.108.162677.
